ArticleInvestigational new drugs2025
Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditis.
Article in Investigational new drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
To explore the regularity and clinical characteristics of pembrolizumab induced myocarditis, and to provide a reference for the diagnosis and treatment of myocarditis. Clinical reports of pembrolizumab induced myocarditis were collected by searching the database as of May 31, 2025. Clinical data were extracted and analyzed statistically. A total of 97 patients were enrolled in the study, with a median age of 70 years (range 25, 89), of which 53(54.6%) were male. The median time for diagnosis of myocarditis was 25 days (range 3, 4050). The common clinical symptoms were dyspnoea (23.7%), shortness of breath (16.5%), and thoracic pain (13.4%). Myositis and/or myasthenia gravis occurred in 43.3% of the patients. These patients with myocarditis may be accompanied by abnormalities in myocardial biomarkers, electrocardiograms, cardiac magnetic resonance and echocardiograms. After the patients discontinued pembrolizumab and received steroid-based immunotherapy, 72.2% of the patients recovered and 26.8% of the patients died. Myocarditis is a rare and fatal immune-related adverse event of pembrolizumab. Cardiac biomarkers, electrocardiograms and echocardiograms should be monitored during the use of Pembrolizumab. Cardiac magnetic resonance or myocardial biopsy can be used to further confirm myocarditis.
Indexed as
Identifiers
40802145What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.